Revenue
No reported data
Neumora Therapeutics, Inc. (NMRA)
Price—Loading quote
Net income
2022
2023
2024
2025
Free cash flow
2022
2023
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Research & development | $176.1M | $200.9M | $142.7M | $91.7M |
| Operating expenses | $241.2M | $263.5M | $252.1M | $135.9M |
| Operating income | −$241.2M | −$263.5M | −$252.1M | −$135.9M |
| EBITDAderived | −$240.9M | −$262.8M | −$251.4M | −$135.3M |
| Net income | −$236.9M | −$243.8M | −$235.9M | −$130.9M |
| Basic EPSper diluted share | -$1.45 | -$1.53 | -$3.63 | -$4.81 |
| Diluted EPSper diluted share | -$1.45 | -$1.53 | -$3.63 | -$4.81 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 17, 2026Form 4 | Aurora Daljit SinghSee Remarks | SellCommon Stock | 6.2K | $3.56 | $21.9K | 82.8K |
| Feb 17, 2026Form 4 | Pinto JoshuaPresident | SellCommon Stock | 6.0K | $3.54 | $21.1K | 57.8K |
| Feb 17, 2026Form 4 | BERNS PAUL LSee Remarks | SellCommon Stock | 9.8K | $3.51 | $34.5K | 7.40M |
| Feb 17, 2026Form 4 · 10b5-1 | Milligan Michael LeeSee Remarks | SellCommon Stock | 1.4K | $3.57 | $5.1K | 21.0K |
| Nov 11, 2025Form 4 · 10b5-1 | Aurora Daljit SinghSee Remarks | SellCommon Stock · indirect | 114.7K | $2.68 | $307.4K | 0 |